Cannabis Extracts Market

Cannabis Extracts Market Forecast and Outlook 2026 to 2036

The global cannabis extracts market is projected to reach USD 32.2 billion by 2036, recording an absolute increase of USD 25.9 billion over the forecast period. The market is valued at USD 6.3 billion in 2026 and is set to rise at a CAGR of 17.7% during the assessment period. Consumption of cannabis extracts is expected to grow by 5.1 times during the same period, supported by increasing demand from medical cannabis applications and expanding adoption in wellness and therapeutic programs across both developed and emerging markets.

Key Takeaways from the Cannabis Extracts Market

• Cannabis Extracts Market Value (2026): USD 6.3 billion
• Cannabis Extracts Market Forecast Value (2036): USD 32.2 billion
• Cannabis Extracts Market Forecast CAGR: 17.7%
• Leading Product in Cannabis Extracts Market: Oil (63.0%)
• Key Growth Regions in Cannabis Extracts Market: North America, Europe, and Asia Pacific
• Top Players in Cannabis Extracts Market: Tikun Olam, CANOPY GROWTH CORPORATION, Tilray, Aurora Cannabis, The Cronos Group, Maricann Inc, Organigram Holdings Inc., Aphria Inc

Growing application diversity in chronic pain management, mental health treatment protocols, and specialized pharmaceutical formulations creates expanding opportunities for cannabis extract innovations and specialized product developments. Rising legalization momentum in North American and European jurisdictions, coupled with expanding medical cannabis infrastructure through licensed cultivation facilities and modern extraction technologies, further accelerate market penetration across diverse therapeutic segments. Rising acceptance of cannabis-based therapies, particularly in pain management and neurological disorder treatment, generates sustained requirements for high-quality extract products and pharmaceutical-grade cannabinoid formulations.

Technical advancements in extraction methods demonstrating measurable improvements in cannabinoid concentration, terpene preservation, and product purity reinforce manufacturer confidence in cannabis extract production economics, while medical research trends toward evidence-based cannabinoid therapies expand addressable market opportunities beyond recreational consumption into regulated pharmaceutical applications.

Cannabis Extracts Market

Metric	Value
Market Value (2026)	USD 6.3 billion
Market Forecast Value (2036)	USD 32.2 billion
Forecast CAGR (2026-2036)	17.7%

Category

Category	Segments
Product Type	Oil; Tinctures
Extract Type	Full Spectrum Extracts; Cannabis Isolates
Source	Marijuana; Hemp
End-Use	Medical Use (Cancer; Chronic Pain; Depression and Anxiety; Arthritis; Diabetes; Glaucoma; Migraines; Epilepsy; Multiple Sclerosis; AIDS; Amyotrophic Lateral Sclerosis; Alzheimer’s; Post-Traumatic Stress Disorder; Parkinson’s; Tourette’s; Others); Recreational Use
Region	North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Segmental Analysis

What makes Oil the Dominant Product Type in the Cannabis Extracts Market?

The oil segment represents the dominant force in the cannabis extracts market, capturing approximately 63.0% of total market share in 2026. This established product category encompasses solutions featuring critical therapeutic functionality for oral administration, sublingual delivery, and topical applications, including CBD oils and THC-dominant formulations that enable precise dosing control, versatile administration methods, and enhanced patient compliance across all medical cannabis applications.

Key advantages driving the oil segment include:

• Established production infrastructure with proven extraction processes that reduce manufacturing complexity and ensure consistent product availability
• Versatile administration options allowing sublingual, oral, and topical delivery across different therapeutic applications without significant formulation modifications

Which Extract Type Category Leads Market Consumption in the Cannabis Extracts Market?

The full spectrum extracts segment represents the dominant force in the cannabis extracts market, capturing approximately 71.0% of total market share in 2026. This leading extract type category encompasses whole-plant cannabinoid profiles, terpene-rich formulations, and entourage effect-optimized products requiring comprehensive cannabinoid and terpene preservation for enhanced therapeutic outcomes and holistic treatment approaches.

The full spectrum extracts segment's market leadership stems from therapeutic advantages attributed to synergistic cannabinoid interactions, with whole-plant extracts providing enhanced efficacy compared to single-compound formulations across diverse medical applications.

Which Source Category Dominates in the Cannabis Extracts Market?

Marijuana-sourced cannabis extracts represent the dominant source, capturing 84.0% of total market share in 2026. This leading source category encompasses high-THC cannabis varieties, medical marijuana cultivars, and recreational cannabis strains providing comprehensive cannabinoid profiles for therapeutic and adult-use applications. Marijuana’s market leadership stems from higher cannabinoid concentrations, diverse strain availability, and established cultivation infrastructure across legalized jurisdictions.

Which End-use Category Leads Market Consumption in the Cannabis Extracts Market?

The medical use segment represents the leading end-use category in the cannabis extracts market, capturing approximately 75.0% of total market share in 2026. This dominant end-use encompasses therapeutic applications for chronic pain management, mental health conditions including depression and anxiety, neurological disorders, and various medical conditions where cannabis extracts provide symptom relief and treatment support. The medical use segment's market leadership stems from growing clinical evidence supporting cannabinoid therapies, expanding medical cannabis legalization, and increasing physician acceptance of cannabis-based treatments.

What are the Drivers, Restraints, and Key Trends of the Cannabis Extracts Market?

The cannabis extracts market is driven by expanding medical cannabis legalization and wider prescription access, which are increasing demand for pharmaceutical-grade extract products. Growing clinical research into cannabinoid-based therapeutics and the approval pipeline for cannabis-derived medicines are further supporting adoption, particularly in regulated medical markets. Technological advances in supercritical CO2 extraction and chromatography purification are also improving cannabinoid isolation efficiency, product purity, and consistency, strengthening clinical and commercial viability.

Market restraints include complex and fragmented regulatory frameworks, banking and financial service restrictions, and conflicts between federal and state-level regulations in certain jurisdictions. Social stigma and hesitation within the medical community continue to limit prescribing confidence, while the absence of standardized dosing guidelines and long-term safety data constrains broader medical integration.

Key trends include increasing participation by pharmaceutical companies in North America and Europe through partnerships, clinical trials, and regulated product development. Standardized extraction protocols, validated analytical testing, and pharmaceutical-grade quality systems are becoming central to market maturation, though regulatory uncertainty remains a key risk to investment momentum.

Analysis of the Cannabis Extracts Market by Key Countries

Country	CAGR (2026-2036)
USA	11.3%
Canada	17.7%
Germany	11.0%
UK	11.2%
Australia	11.1%
Israel	12.0%
Brazil	10.9%

Why does Israel Lead Global Cannabis Extract Growth through Medical Research and Export Strength?

Israel demonstrates the strongest growth outlook in the cannabis extracts market, with a projected CAGR of 12.0% through 2036. Growth is anchored in the country’s advanced medical cannabis research ecosystem, export-oriented production, and pharmaceutical-grade development programs. Medical research institutions and licensed producers are deploying advanced extraction technologies to support both domestic therapeutic use and international pharmaceutical markets.

Strong regulatory oversight and export licensing frameworks enable consistent quality and global market access. Israel’s pioneering cannabinoid research history continues to support clinical validation, positioning the country as a scientific and regulatory benchmark for medical cannabis extracts.

How Does Canada Maintain Market Leadership Through Comprehensive Legalization and Scale?

Canada records a robust 17.7% CAGR through 2036, supported by a mature federal legalization framework and established licensed producer infrastructure. Cannabis extract production is expanding across both medical and recreational channels, with producers investing in pharmaceutical-grade extraction and quality assurance systems.

Integrated supply chains and regulated retail networks enable wide product availability. Growth is reinforced by rising medical patient registrations and sustained recreational demand. Canada’s Cannabis Act provides regulatory clarity, supporting continued capacity expansion and product innovation.

How does the USA Drive Cannabis Extract Growth amid State-Level Legalization?

The USA’s cannabis extracts market grows at an 11.3% CAGR, driven by expanding state-level medical and recreational legalization. Cannabis extract demand is increasing across large patient populations and mature recreational markets.

Multi-state operators are scaling extraction capacity while navigating fragmented regulatory frameworks and interstate trade restrictions. Despite federal constraints, expectations of regulatory reform and continued state adoption support long-term growth. Pharmaceutical cannabinoid development and FDA-approved therapies remain an important emerging focus.

Why is the UK Emerging as a Structured Medical Cannabis Market?

The cannabis extracts market in UK expands at an 11.2% CAGR, driven by growing medical cannabis prescriptions and integration into consultant-led care pathways. Adoption is concentrated in specialist clinics and private healthcare settings, with extracts prescribed for treatment-resistant conditions under clinical supervision.

Import licensing and pharmaceutical distribution partnerships support product availability. Ongoing collaboration between clinicians and research institutions continues to expand the clinical evidence base, reinforcing demand for pharmaceutical-grade extracts.

How does Australia Support Market Growth through Controlled Medical Frameworks?

Australia records an 11.1% CAGR through 2036, supported by the Therapeutic Goods Administration’s regulated medical cannabis framework. Prescribing activity is increasing through the Special Access Scheme and authorized prescriber pathways. Medical practitioners and specialty pharmacies drive demand for pharmaceutical-grade cannabis extracts, emphasizing patient safety and clinical evidence. Structured regulation supports consistent quality and controlled market expansion.

Why does Germany lead European Cannabis Extract Adoption Through Insurance Coverage?

Germany’s market grows at an 11.0% CAGR, supported by statutory health insurance reimbursement and pharmacy-based distribution. Medical cannabis extracts are widely prescribed for chronic pain and other approved indications.

Established pharmaceutical wholesalers and pharmacies ensure standardized dispensing and patient counseling. Strong quality requirements and regulatory oversight position Germany as a central hub for European medical cannabis development.

How is Brazil Developing Cannabis Extract Demand Through Regulatory Progress?

Brazil records a 10.9% CAGR, driven by evolving ANVISA regulations and rising patient advocacy. Medical cannabis access remains centered on import authorization and compassionate use programs, particularly in major urban regions. Patient associations and specialist physicians play a key role in driving adoption. Regulatory progress is gradually expanding market access, creating early-stage opportunities for cannabis extract therapies focused on chronic and severe conditions.

Competitive Landscape of the Cannabis Extracts Market

The cannabis extracts market includes an estimated 50 to 70 meaningful participants and shows moderate concentration, with leading producers benefiting from scale, regulatory experience, and established medical and recreational distribution networks. Competition is shaped by product consistency, pharmaceutical-grade extraction capability, regulatory compliance, and access to legalized markets.

Market leaders such as Tikun Olam, Canopy Growth Corporation, and Tilray maintain strong positions through diversified extract portfolios, international operations, and expertise in medical-grade cannabis production. These companies leverage established cultivation assets, standardized extraction processes, and ongoing capacity expansion to support medical, wellness, and export-oriented demand.

Challenger firms including Aurora Cannabis, The Cronos Group, and Aphria Inc. compete through broad product ranges and strong regional footprints in key legalized jurisdictions. Specialty producers such as Maricann Inc. and Organigram Holdings Inc. focus on niche segments, emphasizing organic cultivation, differentiated strains, and premium extract formulations.

Regional and emerging players intensify competition through craft-scale production and early entry into newly legalized markets, particularly European medical markets and select Asia Pacific regions. Overall competitiveness favors firms with robust quality management systems spanning genetics, extraction, processing, and regulated distribution.

Key Players in the Cannabis Extracts Market

• Tikun Olam
• Canopy Growth Corporation
• Tilray
• Aurora Cannabis
• The Cronos Group
• Maricann Inc
• Organigram Holdings Inc.
• Aphria Inc

Scope of the Report

Items	Values
Quantitative Units	USD 6.3 Billion
Product Type	Oil, Tinctures
Extract Type	Full Spectrum Extracts, Cannabis Isolates
Source	Marijuana, Hemp
End-use	Medical Use (Cancer, Chronic Pain, Depression and Anxiety, Arthritis, Diabetes, Glaucoma, Migraines, Epilepsy, Multiple Sclerosis, AIDS, Amyotrophic Lateral Sclerosis, Alzheimer's, Post Traumatic Stress Disorder, Parkinson's, Tourette's, Others), Recreational Use
Regions Covered	North America, Europe, Asia Pacific, Latin America, MEA
Country Covered	USA, Canada, Germany, UK, Australia, Israel, Brazil, and 40+ countries
Key Companies Profiled	Tikun Olam, CANOPY GROWTH CORPORATION, Tilray, Aurora Cannabis, The Cronos Group, Maricann Inc, Organigram Holdings Inc., Aphria Inc
Additional Attributes	Dollar sales by product type, extract type, source, and end-use categories, regional legalization trends across North America, Europe, and Asia Pacific, competitive landscape with licensed cannabis producers and pharmaceutical companies, product specifications and quality requirements, integration with medical cannabis programs and pharmaceutical distribution systems.

Cannabis Extracts Market by Segments

• Product Type :

  • Oil
  • Tinctures

• Extract Type :

  • Full Spectrum Extracts
  • Cannabis Isolates

• Source :

  • Marijuana
  • Hemp

• End-use :

  • Medical Use
    • Cancer
    • Chronic Pain
    • Depression and Anxiety
    • Arthritis
    • Diabetes
    • Glaucoma
    • Migraines
    • Epilepsy
    • Multiple Sclerosis
    • AIDS
    • Amyotrophic Lateral Sclerosis
    • Alzheimer's
    • Post Traumatic Stress Disorder
    • Parkinson's
    • Tourette's
    • Others
  • Recreational Use

• Region :

  • North America
    • USA
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Netherlands
    • Italy
    • Switzerland
    • Rest of Europe
  • Asia Pacific
    • Israel
    • Australia
    • Japan
    • South Korea
    • India
    • ASEAN
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • MEA
    • Saudi Arabia
    • Other GCC Countries
    • Turkey
    • South Africa
    • Rest of MEA